New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion Program

Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced results of research that highlighted the positive impact of the growing interest in anti-obesity medications on Allurion Program awareness and uptake.

The global market for anti-obesity medications – specifically of GLP-1s (glucagon-like peptide-1 receptor agonists) – is expected to reach $100 billion by 2030.¹ Research has shown these products have significantly altered the treatment landscape and drawn further attention to the urgent need to tackle the obesity crisis.

In September 2023, Allurion conducted a survey of 172 healthcare professionals to measure the potential impact of GLP-1 growth on Allurion Program awareness among Allurion patients and healthcare professionals (HCPs).

The results offer valuable insights into how GLP-1s have influenced perceptions and attitudes towards medical weight-loss generally, and the role the Allurion Program can play in helping patients who are looking for a more holistic approach to weight loss.

More specifically, the survey responses highlight a belief among HCPs that the introduction of anti-obesity medications like GLP-1s have had a positive impact on raising awareness of, and generating interest in, other medical weight-loss treatment options, including the Allurion Program.

Key findings included:

• Close to one-third of HCPs said patients had tried GLP-1s before starting the Allurion Program. According to the survey results, the 3 main factors influencing their decision to begin the Allurion Program were their doctor’s recommendation; a preference for avoiding the unwanted effects of weight-loss drugs; and the ability of the Allurion Program to support rapid weight loss.
• 89% of HCPs believed the Allurion Program represented an ideal first-line treatment to achieve at least 10% total body weight loss in a fast and sustainable way
• HCPs offering GLP-1s experienced a 59% increase in patient enquiries about other medically-led weight-loss treatments
• 45% of HCPs believed the new anti-obesity medications had boosted awareness of, and interest in, the Allurion Program, and 34% of HCPs said they had no impact

Allurion also surveyed 1,663 Allurion Program patients from 64 markets. Results generally mirrored those of the HCP research.